1/17
Pressure BioScience – PBIO OTCQB – Converts Debt
To Equity -In Breakout Mode – Target $4.00
thestreetreports.com/pressure-bioscience-pbio-otcqb-converts-debt-to-equity-in-breakout-mode-target-4-00
WALL STREET NEWS
CEO Game Changer Interview
BREAKOUT ALERT
PRESSURE BIOSCIENCES INC
OTC PBIO
Converts $10 Mill Debt To Equity
Revolutionize Edible Cannabis Industry
China Orders 16 Units
Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC -Cell :
516 – 455-7662 – Email – gzplumtree@gmail.com
Latest Video CEO Interview
These shares are in BREAKOUT TERRITORY having rapidly advanced from $0.91 cents to
$1.90 over the past weeks . We look for a target of $4.00 based on technical breakout
above $2.00

2/17
We urge all serious investors to immediately place these shares on their Buy List
**************************************
Pressure BioSciences Announces the Exchange of Over $10 Million of
Debt into Equity
Company’s Largest Investor Exchanges First Seniority Debt into Non-Secured
Equity at 38% Above-Market Price, Expressing Confidence and Support
SOUTH EASTON, MA / ACCESSWIRE / March 1, 2023 / Pressure BioSciences, Inc.
(OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of
broadly enabling, high-pressure-based products and services to the life sciences and other
industries, today announced that the Company’s largest shareholder has exchanged over $10
million of senior secured debt into unsecured preferred stock. The debt being converted is
comprised of convertible promissory notes, accrued and unpaid interest on all promissory
notes issued to the investor since November 2019, plus accrued and unpaid dividends on the
Company’s Series AA Convertible Preferred Stock purchased by the investor since May 2018.
The $10+ million of debt exchanged into equity represents over 50% of the total debt
currently owed to the Investor by the Company and represents over 30% of the Company’s
total outstanding debt held by all investors through February 2023 via (i) convertible
promissory notes; (ii) accrued and unpaid interest on convertible promissory notes; and (iii)
accrued and unpaid dividends earned from investments in the Company’s Series AA
Convertible Preferred Stock financing. The exchange of debt to equity was consummated at a
value of $2.50 per share of Common Stock, which is an approximate 38% premium over the
Company’s recent open market valuation.
The Company recently announced a number of significant achievements and collaborations,
particularly related to its revolutionary Ultra Shear™ Technology (“UltraShear™”) platform
for its “best-in-class” nanoemulsion processing. Among these are: (i) the development of
“next generation” anti-aging skincare and hair regrowth products with partner Dr. Denese

3/17
SkinScience; (ii) the development of a sports performance/recovery drink with NBA legend
Isiah Thomas’ One World Products (OTCQB: OWPO); and (iii) the release of dramatic
consumer testing results, indicating that PBIO’s UltraShear platform is forging a game-
changing future for the cannabis, nutraceuticals, and supplements industries.
Mr. Richard T. Schumacher, President and CEO of PBIO, commented: “The PBIO Team is
delighted with the strong recent progress in multiple aspects of our business. We are
redesigning our production facilities, adding to our team, strengthening our core
capabilities, filing additional UltraShear patents, building instrument inventories, and
expanding our list of existing and prospective 2023 customers. We are engaging deeper into
building strong strategic partnerships with key companies and individuals, including several
billion-dollar companies who are global best-in-class players in priority markets targeted for
explosive growth. In addition, we have begun forging stronger relationships with multiple
strategic and retail investors.”
Mr. Schumacher continued: “It has been a long time since I’ve seen and felt such excitement,
enthusiasm, and confidence in the future of PBIO within our shareholder base. We believe
this announced conversion of debt into equity is only the beginning of continued
strengthening in our financial position and outlook. We are in discussions with other large
shareholders who have expressed similar interest in supporting the Company through
continuing improvements in our balance sheet, by exchanging additional millions of dollars
of debt into equity, following the confidence and leadership demonstrated by the Company’s
long-standing, largest investor. We anticipate additional similar announcements in the
coming weeks.”
Mr. Jeffrey N. Peterson, Chairman of PBIO, added: “The PBIO team has demonstrated
tremendous dedication and execution in converting their vision and planning for our patent-
protected nanoemulsions breakthrough technology into a proven reality that is already
demonstrating the transformational power to restate the basis for competition in multiple
multi-billion-dollar markets, spanning nutraceuticals, cosmeceuticals, pharmaceuticals,
food and beverage, agrochemicals, and industrial markets. We are deeply appreciative for
the patience and confidence demonstrated by our largest investor in this pivotal decision,
and to all our investors who have delivered us to this inflection point, as we accelerate
forward through commercialization, growth, capacity expansion, further capitalization,
uplist to NASDAQ/NYSE, and our expected transition to profitability during the next year.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT
is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions safely
and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil & plant biology,

4/17
forensics, and counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of our pressure-based technologies in the following areas: (1) the
use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold”
technology) to allow entry into the bio-pharma contract services sector, and (2) the use of
our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils
and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved using existing
non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels of
activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,”
“anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the
negative of such terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about future events. You
should not place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may differ materially.
These and other factors may cause our actual results to differ materially from any forward-
looking statement. These risks, uncertainties, and other factors include, but are not limited
to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by law.
Pressure BioSciences’ Breakthrough UltraShear Nanoemulsion
Processing Could Help Revolutionize The Edible Cannabis Industry
Earlier this month, Pressure BioSciences, Inc. (OTCQB: PBIO) announced potentially
ground-breaking results from a consumer focus group testing a THC oral spray developed
using the company’s innovative UltraShear™ Technology nanoemulsification platform. The
oral spray boasted strong potency and extremely fast absorption that could put it on track to
become a best-in-class cannabis product in terms of speed to effects, stability, and
bioavailability. The THC oral spray tested in this consumer focus group is being developed in
partnership with California-based cannabis manufacturer, Crème De Canna.
The news comes on the heels of the company’s December announcement of its first
commercial shipment of a CBD oral spray manufactured with the same UltraShear
technology. The $75,000 shipment to Safer Medical of Montana is the first of many
shipments the company expects to make to distributors of CBD products throughout the

5/17
U.S. during 2023. In recent press releases, PBIO has stated that CBD products
manufactured using its patented UltraShear platform could potentially yield many millions
in revenue before the end of its 2023 fiscal year.
WEBSITE PRODICTS TEAR SHEET SEC FILINGS PRESENTATION
Slow And Inconsistent THC Absorption Remains A Key Challenge
for Cannabis Manufacturers
Because cannabinoids, like the well-known THC and CBD, are oil-soluble rather than water-
soluble, the human body struggles to absorb them efficiently. As a consequence, much of the
active ingredient in edible cannabis products is absorbed slowly, intermittently, or hardly at
all.
In one review of cannabis research, only 4% to 12% of THC was absorbed by the body when
taken orally. Not only does that mean that the majority of the THC in an edible ends up
getting wasted, but the variation in bioavailability between 4% and 12% is highly significant.
A consumer eating the same edible product from the same manufacturer with the same dose
might absorb just 4% one day but 12% the next day, leading to very different results.
This makes it incredibly difficult for manufacturers to achieve precise dosing and effects in
their edibles. It also increases production costs since they often need to include more than
the minimum effective dose to compensate for the fact that most of the active ingredients
won’t be absorbed.
In addition to inefficient and inconsistent cannabinoid absorption, another challenge in the
edible cannabis industry is absorption time. It is estimated to take anywhere from 30
minutes to two hours from the time a consumer ingests an edible to the time they start to
feel its first effects, and then up to four hours to achieve peak effects.
“Impatient consumers may repeatedly consume their edibles, only to be unhappily
overdosed shortly thereafter,” explained PBI’s Director of Sales and Marketing, John
Hollister in a statement on the consumer testing results. For patients using cannabis as a
treatment for pain, anxiety, or depression, that delayed response also means edible cannabis
is often unable to provide the instant relief they need.
While smoking or vaping comes with a higher bioavailability of around 30% and a faster
response time of seconds or minutes, the respiratory health consequences make it a less-
than-ideal option, especially for regular use.
PBI’s UltraShear Nanoemulsion Technology Could Be A
Breakthrough In Achieving Precision Dosing for THC, CBD, and
Other Products
Consumers in the focus group reported that the first effects could be felt less than 10
minutes after initially using the innovative UltraShear processed THC oral spray, with many
reporting noticeable effects within 1-5 minutes. Peak effects were achieved between 15-60

6/17
minutes after taking the dose. The results of this initial focus group could be a game-changer
for an industry that’s been struggling with the challenges around consistent dosing and
effective non-inhalation absorption.
“This testing has provided dramatic consumer-level validation in the cannabis market for
our UltraShear nanoemulsion capabilities and for its expected market-changing impact,”
said Mr. Hollister.
The UltraShear technology used to make the oral spray is PBI’s patented pressure-based
platform that’s capable of creating what the company describes as the “best-in-class”
nanoemulsions worldwide. In the cannabis nanoemulsion, the oil drops containing the CBD
or THC molecules are sheared down to a nanosize so small that they are effectively water-
soluble. This makes for a significantly more easily absorbed product that can be more
precisely and accurately dosed.
For consumers, that means more immediate and consistent effects every time they use an
UltraShear processed oral spray or other mechanisms for ingestion. For manufacturers, that
improved bioavailability means smaller amounts of THC or CBD are required to achieve an
effective dose since the less active ingredient is getting wasted – thus saving the
manufacturer money.
“It provides an easy-to-use, reliable, and healthy alternative dosing format, with nearly
immediate onset and a consistent experience associated with inhaling, but without the
respiratory health risks associated with smoking and vaping. It also eliminates the
frustrating delayed effects, imprecision, and frequent overdosing associated with edibles,”
said Crème De Canna President, Jonathan Kolodinski.
This article was originally published on Benzinga here .
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure.
PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions
safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterror applications. Additionally, major new market
opportunities have emerged in the use of our pressure-based technologies in the following
areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the
“BaroFold” technology) to allow entry into the bio-pharma contract services sector, and
(2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible
fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-
life or room temperature stable low-acid liquid foods that cannot be effectively preserved
using existing non-thermal technologies.

7/17
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels
of activity, performance, or achievements to be materially different from any future
results, levels of activity, performance or achievements expressed, implied, or inferred by
these forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,”
“plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or
“continue” or the negative of such terms and other comparable terminology. These
statements are only predictions based on our current expectations and projections about
future events. You should not place undue reliance on these statements. In evaluating these
statements, you should specifically consider various factors. Actual events or results may
differ materially. These and other factors may cause our actual results to differ materially
from any forward-looking statement. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under the heading “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31,
2021, and other reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information included in this
release, except as otherwise required by law.
This post contains sponsored advertising content. This content is for informational
purposes only and is not intended to be investing advice.
Pressure BioSciences Receives Record Nearly $600,000 Order for 16
PCT Instruments From Peoples Republic Of China
Largest Single Order in Company’s History was Prepaid as New Chinese
Distributor Comes Online;
Adds to Revenue Strength Also Building Across PBI’s UltraShear
Nanoemulsions Platform
SOUTH EASTON, MA / ACCESSWIRE / February 1, 2023 / Pressure BioSciences,
Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a global leader in the development and sale
of broadly enabling, high-pressure-based products and services to the life sciences and other
industries, today announced entrance into an exclusive distribution agreement for the
People’s Republic of China (“Agreement”) with PRS International Trade (Shanghai) Co., Ltd.
(“PRS International”).
Reflecting confidence built upon PBIO’s long investment in developing worldwide market
support for the Company’s Pressure Cycling Technology (“PCT”) platform, PRS
International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly
$600,000, with a commitment to purchase additional units and related consumables before
the end of 2023. This historic purchase of PBIO’s original high-pressure technology
instruments comes on the back of a surge in purchase orders for all product categories of the
Company’s pressure-based instruments and consumables.

8/17
Director of Sales and Marketing John B. Hollister commented, “We believe this purchase of
a record number of Barocycler EXT instruments, together with strong worldwide indications
of purchase plans for additional non-PCT instruments and consumables, indicates that
China and the rest of the life sciences world is finally emerging from under the economic
cloud of COVID. We expect first quarter 2023 sales to benefit from the initial shipment of up
to five Barocycler EXT instruments to China, from the surge in orders we are experiencing in
our other pressure-based instrument areas (e.g., Barocyclers, HUB pressure generators, and
cell disruptors), and from our recently opened UltraShear™ nanoemulsions tolling services.
Adding to this excitement, we had a few expected sales in 2022 slip into 2023 due to supply
chain issues. The net effect is that we are having a terrific first quarter, which we believe will
continue to strengthen throughout 2023 and beyond.”
Richard T. Schumacher, President and CEO, expanded: “We have been focusing the majority
of our efforts on the launch of our revolutionary UltraShear nanoemulsions processing
platform, which we expect will lead to ramping revenue in 2023. Additionally, our long-term
investment in building broad-based market support for our line of pressure-based
instruments continues to pay off with growing penetration and adoption for our initial high-
pressure technology platforms and application areas. Our commitment to supporting this
key area of our business remains unwavering. We are honored and humbled by the large,
prepaid order from PRS International, and we are delighted to be in a position to reinvest
our strengthening technical and financial foundation in support of our next generation
UltraShear nanoemulsions technology platform that we believe will be manifesting strong
commercial traction starting in this quarter.”
Jeffrey N. Peterson, Chairman of PBIO, observed, “Ric and his team were visionaries in
building strong scientific support and credibility in the Company’s initial PCT platform
technology and applications areas. While we see market opportunities growing into the tens
of millions of dollars for this platform in the coming years, our strategic focus has
appropriately advanced onto our BaroFold and now our UltraShear platforms. BaroFold is
an applications arena that we believe offers future potential growth that could be multiples
greater for PBIO than the PCT product line. However, our investment in the development of
the UltraShear™ platform, for the production of extremely stable and bioavailable
nanoemulsions of oil-soluble active molecules for effective delivery into humans, animals,
and plants, is a game-changing technology that we believe offers PBI opportunities into the
hundreds of millions of dollars, if not more, as it re-defines the basis of competition in
multiple multi-billion dollar industries, from pharmaceuticals to nutraceuticals,
cosmeceuticals, food/beverage, agrochemicals, and more.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT
is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions safely
and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and

9/17
development, biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of our pressure-based technologies in the following areas: (1) the
use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold”
technology) to allow entry into the bio-pharma contract services sector, and (2) the use of
our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils
and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved using existing
non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels of
activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,”
“anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the
negative of such terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about future events. You
should not place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may differ materially.
These and other factors may cause our actual results to differ materially from any forward-
looking statement. These risks, uncertainties, and other factors include, but are not limited
to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by law.
Pressure BioSciences and One World Products Announce Partnership in
Development of CBD-Nanoemulsion Sports Performance/Recovery
Drinks
NBA Legend Isiah Thomas Leads Effort to Innovate and Deliver Next
Generation Sports Drinks
SOUTH EASTON, MA / ACCESSWIRE / January 27, 2023 / Pressure BioSciences,
Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a global leader in the development and sale
of broadly enabling, high-pressure-based products and services to the life sciences industry,
and One World Products, Inc. (OTCQB: OWPC) (“OWPC”), the largest Black-controlled,
fully-licensed hemp and cannabis producer in Colombia, today announced they have entered
into an active collaboration agreement (“Agreement”) under which the two companies will
combine their strong, symbiotic capabilities to develop an innovative line of next generation
sports performance/recovery drinks.

10/17
The Sports Performance/Recovery Drink Market encompasses live sports performance
optimization, rapid and effective full recovery post-performance, and health and wellness
areas – including immune health and antioxidant benefits. Fast delivery and uptake of
therapeutic and nutritional ingredients must be made effective for the many oil-soluble
active ingredients used in sports drinks. This is where PBIO’s revolutionary UltraShear™
nanoemulsions platform technology is already demonstrating game-changing results across
multiple major consumer market applications. The “Recovery” market has also been
supported by increasing numbers of consumers who consider themselves “non-athletes”
joining in the sports drink craze. Data from IRI put sales of sports/performance beverages at
about $9.5 billion for 2021 (sports drink market 2021).
Isiah Thomas, Chairman and CEO of OWPC, highlighted: “This revolutionary new line of
sports performance/recovery drinks will contain OWPC’s premium quality CBD that has
been processed into a highly stable and extremely bioavailable nanoemulsion by PBIO’s
patented UltraShear technology platform. This next generation CBD-nanoemulsion
beverage is being designed for fast reduction of inflammation and pain, improved recovery
time, and enhanced overall performance – all to be achieved quicker than any competing
drink on the market today. It is being formulated to help athletes push through the tough
moments of a workout or competition, and to recover more quickly afterward. In
professional and even amateur sports, athletes understand the criticality of peak
performance and recovery.”
Mr. Thomas continued: “OWPC has been a highly sought after choice for the development of
new and premium technologies for delivery of hemp and cannabis-derived products. I am
excited that we have an opportunity to pair our premium quality CBD product with PBIO’s
proprietary, cutting-edge nanoemulsification technology to deliver a uniquely-innovative
and effective product to market that we believe will offer unmatched rapid absorption and
full dosing of hard-to-deliver oil-soluble ingredients – to achieve game-changing
performance.”
Richard T. Schumacher, President and CEO of PBIO, expanded: “Partnering with Isiah and
his exceptional team at OWPC is an extraordinary opportunity for PBIO to accelerate the
visibility and impact of our revolutionary UltraShear nanoemulsions platform technology.
Isiah is a world-renowned figure in the world of sports and more broadly as a role model in
Black-owned business leadership, and it is a privilege for our companies to team up! OWPC
has become a leading producer of the highest quality and sustainably sourced hemp-derived
CBD in Colombia, and is closely partnered with their government and indigenous
populations. Teamed with PBIO’s best-in-class nanoemulsions processing, OWPC is
uniquely positioned to deliver these solutions and drive rapid recognition and acceptance
across the worlds of professional and amateur sports. This is going to be exciting and, we
believe, very successful!”
About One World Products, Inc.
One World Products (OTCQB: OWPC) is the largest Black-controlled, fully licensed hemp
and cannabis producer with offices in Las Vegas, Nevada, and offices and operations in
Bogota and Popayan, Colombia. One World Products planted its first crop of cannabis in

11/17
2018 at its cultivation site in Popayan, Colombia, and began harvesting commercially in the
first quarter of 2020.
About Mr. Isiah Thomas
Isiah Thomas was inducted into the National Basketball Association (NBA) Hall of Fame in
2000 after spending his entire career with the Detroit Pistons. He was a 12-time NBA All-
Star, a two-time NBA champion, the 1990 NBA Finals Most Valuable Player, and named as
one of the 50 Greatest Players in NBA History. Today, Mr. Thomas serves as an analyst for
NBA TV and is an accomplished and highly respected international business executive and
investor. His portfolio of companies was developed through Isiah International, Inc., which
invests in companies with strong market positions and growth potential.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT
is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions safely
and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of our pressure-based technologies in the following areas: (1) the
use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold”
technology) to allow entry into the bio-pharma contract services sector, and (2) the use of
our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils
and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved using existing
non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels of
activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,”
“anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the
negative of such terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about future events. You
should not place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may differ materially.

12/17
These and other factors may cause our actual results to differ materially from any forward-
looking statement. These risks, uncertainties, and other factors include, but are not limited
to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by law.
Pressure BioSciences Nanoemulsions Platform Forging Game-Changing
Future for Cannabis Industry
Dramatic Consumer Testing Results Confirm UltraShear Nanoemulsion THC
Oral Spray Delivers First Effects and Maximization in Lightning Speed –
Simple, Reliable Dosing Delivers Profoundly Improved Results
SOUTH EASTON, MA / ACCESSWIRE / January 19, 2023 / Pressure BioSciences,
Inc. (OTCQB:PBIO) (“PBI” or “Company”) today announced results from initial consumer
focus group testing of a THC Nanoemulsion Oral Spray prepared using PBI’s revolutionary
Ultra Shear Technology™ (UltraShear™ or UST™) platform. Preparation of the THC
Nanoemulsion Oral Spray was completed by PBI’s California-based partner companies,
including Crème De Canna (CdC), a CA-licensed manufacturer and long-established
provider of innovative, high-quality cannabis products in CA.
Mr. John B. Hollister, PBI’s Director of Sales and Marketing, explained: “Cannabinoids like
THC are oil-soluble molecules that are typically poorly absorbed when ingested by our
water-based human bodies. For THC edibles, most consumers report waiting 30-60 minutes
for first effects and 60-90 minutes to peak effects. Impatient consumers may repeatedly
consume their edibles, only to be unhappily over-dosed two hours later. Conversely,
smoking and vaping produce first effects immediately and peak effects quickly but are
increasingly in disfavor for the well-known respiratory health consequences that
accumulate.”
Mr. Hollister continued: “PBI’s partners in California used our revolutionary UltraShear
platform to prepare extreme nanoemulsions of THC into an Oral Spray for consumer testing.
Multiple test groups have confirmed that the UltraShear Nanoemulsion THC Oral Spray
produces first effects between 1-10 minutes, often in the first 1-5 minutes, with peak effects
reached in 15-60 minutes, often within 15-30 minutes. This testing has provided dramatic
consumer-level validation in the cannabis market for our UltraShear nanoemulsion
capabilities and for its expected market-changing impact. We are anticipating substantial
revenues from the first THC UltraShear Nanoemulsion Oral Spray to be marketed by our
California partners, beginning in this quarter.”
Must See CEO VIDEO – Recent Podcast
Mr. Jonathan Kolodinski, President of CdC, said: Crème De Canna is very excited to partner
with PBI on the development of this groundbreaking dosing modality that will disrupt the
global cannabis marketplace. This innovative product has strongly addressed the needs and
concerns from both the edibles and inhalation sides of the cannabis consumer marketplace.
It provides an easy to use, reliable, and healthy alternative dosing format, with the

13/17
immediate onset and consistent experience associated with inhalables but without the
respiratory health risks, and it eliminates the frustrating delayed effects, imprecision, and
frequent overdosing associated with edibles, as well as the calories!”
Mr. Kolodinski further stated: “Utilizing PBI’s UST platform, we successfully formulated
cannabinoids into a clear, effectively water-soluble, extremely fine nanoemulsion that is
conveniently and effectively delivered via an oral mist, providing the consumer with near-
immediate onset and rapid peak effects. The consumer testing results announced today
herald the dramatic reshaping we expect will follow in the cannabis markets. We are excited
to continue to research the impacts of various combinations of cannabinoids, terpenoids,
and other compounds to produce highly functional cannaceutical products to improve the
lives of people around the world.”
Mr. Jeffrey N. Peterson, Chairman of PBI, summarized: “It was extremely satisfying to see
our consumer study objectives in assessing THC UltraShear Nanoemulsions for absorption
speed and potency, easy and precise dosing, and avoidance of the slow and unreliable
under/over-dosing of edibles so well demonstrated. Nonetheless, this was fully anticipated
based upon the UltraShear platform’s astonishing demonstrated successes to date across
applications spanning industries from pharmaceuticals and nutraceuticals to
cosmeceuticals, food and beverages, agrochemicals, and more. PBI’s UltraShear platform
offers a game-changing redefinition of the terms of competition for our partners addressing
these diverse multi-billion-dollar market opportunities, and we are very excited about the
path ahead for PBI and our partners in 2023 and beyond.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT
is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions safely
and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of our pressure-based technologies in the following areas: (1) the
use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold”
technology) to allow entry into the bio-pharma contract services sector, and (2) the use of
our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils
and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved using existing
non-thermal technologies.
Forward Looking Statements

14/17
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels of
activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,”
“anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the
negative of such terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about future events. You
should not place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may differ materially.
These and other factors may cause our actual results to differ materially from any forward-
looking statement. These risks, uncertainties, and other factors include, but are not limited
to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by law.
Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales
Followed by Rapid Revenue Growth from Multiple Large Industries in
2023
Foundations Built and Momentum Achieved in 2022 Expected to Drive
Company to Significant Revenue Levels, Up-list, and Profitability in 2023: The
Stage Has Been Set
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2022 / Pressure BioSciences,
Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of
broadly enabling, pressure-based instruments, consumables, and specialty process
development and production services to the worldwide nutraceuticals, cosmetics,
biotherapeutics, and food/beverage industries, among others, today offered guidance that
the Company believes its Q4 2022 revenue will exceed quarterly revenue for any quarter
over the past four years, and may achieve the highest quarterly revenue ever for the
Company. PBI believes the foundations built and momentum achieved over the past several
months will continue to accelerate, driven primarily by the recent commercial release of its
revolutionary Ultra Shear Technology™ (UltraShear™ or UST™) platform. The Company
further believes Q1 2023 revenue will greatly exceed Q4 2022’s expected strong results, and
that revenues in each successive quarter will surpass the prior quarter’s level. Management
expects the Company to reach breakeven/profitability by the end of 2023.
Future Outlook (The Stage Has Been Set): Q4 2022 & FY 2023.
Revenue
Q4 2022: PBI expects to report highest quarterly revenue in past 4 years, likely
highest ever.
FY 2023: each quarter expected to exceed prior quarter’s revenue. UltraShear
revenues expected to top $10M for 2023, beginning with over $1M in Q1 2023.

15/17
Agreements (UltraShear Toll Processing)
Company ending 2022 with 4 executed agreements; very close to final execution
of six or more agreements.
Each agreement estimated to yield $1M or more in incremental annual revenue.
CBD
Expect data releases in Q1 2023 from key opinion leaders in academia and
patient treatment/advocacy, supporting PBI’s UltraShear Nano-CBD as among
Best-in-Class in Bioavailability globally.
THC
MA and CA market focus group studies underway to demonstrate expected
superior speed of onset and absorption, supporting PBI’s UltraShear Nano-THC
as among Best-in-Class in Bioavailability globally.
Nutraceutical Supplements
Supply agreement with several multi-billion-dollar nutraceutical supplement
leaders to be closed by mid-2023; strategic investment expected.
Immune Booster
Discussions underway with quality-leading, top-selling suppliers seeking
assistance to nanosize oil-based active ingredients to be included in new,
powerful Immune Booster product…including PBI’s proven capabilities in
curcumin, astaxanthin, and CBD.
Cosmetics:
PBI anticipates the Dr. Denese SkinScience partnership will strongly leverage
data generated in 2022 studies of PBI’s UltraShear processed Retinol and Lipid-
Soluble Vitamin C, and from current on-going studies, to powerfully validate
capabilities of UltraShear-enabled, next-generation, anti-aging serums from Dr.
Denese, and will drive new achievements from her existing QVC marketing
engine (with over $500M sales over 20 years), starting in Q1 2023.
How the Stage was Set: Review of FY 2022 Key Accomplishments
April: critical pivot in business focus from PCT Platform to Ultra Shear Technology
Platform.
April: early access program for UltraShear nanoemulsion processing platform
announced.
May: first agreement to make UltraShear-based Nano-CBD product – expected 2023
product revenues of $1M.
June: PBI partner Ohio State publishes/presents data to support UltraShear role in
global $41B plant protein market.
July: second $1M+ agreement to process commercial UltraShear-based Nano-CBD
products announced.
August: third agreement to process commercial Nano-CBD products. Projected FY
2023 revenues to exceed $3M.
August: PBI secures pivotal partnership with Dr. Denese SkinScience – QVC leader
with $500M 20-year sales.
October: PBI and Dr. Denese announce UltraShear-enabled anti-aging and hair
regrowth products for 2023 release.

16/17
December: Dr. Denese reports data on UltraShear Nano-Retinol greatly exceeds all
performance expectations.
December: first commercial production of revolutionary UltraShear processed Nano-
CBD product shipped and paid.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “Our development of
UltraShear over the past 6 years presented a pivotal, game-changing nanoemulsions
technology that we believe will restate the basis of competition for a myriad of products
across multiple major industries. We have assembled a strong and differentiated IP position
and unique engineering and scientific expertise to unleash this opportunity, for PBI and for
clients worldwide. We made the critical decision in early 2022 to pivot our business focus
and resources almost entirely onto accelerating the UltraShear platform, building
commercial-stage UST processing equipment, creating pivotal technology demonstrations
with select partners in multiple industries, and accelerating our path to commercial traction
and a revenue growth inflection.”
Mr. Schumacher concluded: “Our team has navigated a very challenging path to the
achievement of this pivot point, and we are proud of what we have built. The stage has been
set. Initial partners have been secured and our first commercial UltraShear product has been
delivered and paid. Astonishing early demonstrations of UltraShear’s unique differentiation
of products continue to mount up, and more partners and early marketing results are
gathering already for revenue acceleration in Q1 and throughout all of 2023. We are grateful
daily for the patient support of our many long-term investors, and we are excited to have
them at our side as PBI enters an exciting new era of revenue growth, profitability, and a
planned uplist to a national exchange in 2023.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of
innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and
other industries. Our products are based on the unique properties of both constant (i.e.,
static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT
is a patented enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to control bio-molecular interactions safely
and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the
development of PCT-based products for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of our pressure-based technologies in the following areas: (1) the
use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold”
technology) to allow entry into the bio-pharma contract services sector, and (2) the use of
our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils
and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room
temperature stable low-acid liquid foods that cannot be effectively preserved using existing
non-thermal technologies.

17/17
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future
events or our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our or our industry’s actual results, levels of
activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,”
“anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the
negative of such terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about future events. You
should not place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may differ materially.
These and other factors may cause our actual results to differ materially from any forward-
looking statement. These risks, uncertainties, and other factors include, but are not limited
to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed
by the Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise required by
law.Neither PSN nor its owners, members, officers, directors, partners, consultants, nor
anyone involved in the publication of this website, is a registered investment adviser or
broker-dealer or associated person with a registered investment adviser or broker-dealer
and none of the foregoing make any recommendation that the purchase or sale of
securities of any company profiled in the PSN website is suitable or advisable for any
person or that an investment or transaction in such securities will be profitable. The
information contained in the PSN website is not intended to be, and shall not constitute, an
offer to sell nor the solicitation of any offer to buy any security. The information presented
in the PSN website is provided for informational purposes only and is not to be treated as
advice or a recommendation to make any specific investment. Please consult with an
independent investment adviser and qualified investment professional before making an
investment decision.d. Writer is paid $925/mo by company